Cascadian Therapeutics
Aug 8, 2017

Cascadian Therapeutics Reports Second Quarter 2017 Financial Results

First Patients Randomized in Western Europe and Australia in Ongoing Global HER2CLIMB Registrational Trial of Tucatinib

Conference Call Scheduled for Today at 4:30 p.m. ET

SEATTLE, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2017, and provided an update on tucatinib, an investigational oral, small molecule kinase inhibitor that is highly selective for HER2 and the Company's lead product in development.

"During the second quarter, we were pleased to receive confirmation from the European Medicines Agency (EMA) that HER2CLIMB, if positive, could serve as a single registrational trial for submission to the European regulators for potential marketing approval, and that tucatinib was granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of breast cancer patients with brain metastases," said Scott Myers, President and CEO of Cascadian Therapeutics. "We are now enrolling patients in HER2CLIMB on three continents. We are pleased with site activations and patient enrollment, which are currently ahead of our projections in North America."

Second Quarter and Recent Highlights

Second Quarter Financial Results

2017 Financial Outlook

Cascadian Therapeutics expects operating expenses in 2017 to be slightly higher than in 2016, primarily due to an increase in activities related to the ongoing worldwide HER2CLIMB pivotal trial. Cash used in operations for 2017 is expected to be approximately $50.0 million to $54.0 million.

Cascadian Therapeutics believes the above financial guidance to be correct as of the date provided and is providing the guidance as a convenience to investors and assumes no obligation to update it.

Conference Call Information

Cascadian Therapeutics management will host a conference call and live audio webcast to review its second quarter financial results and provide an update on business activities today at 1:30 p.m. PT / 4:30 p.m. ET. Participants can access the call at +1 (877) 280-7291 (domestic) or +1 (707) 287-9361 (international). To access the live audio webcast or the subsequent archived recording, visit the Events & Presentations page of the News & Events section of the Cascadian Therapeutics' website at

About Cascadian Therapeutics

Cascadian Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates for the treatment of cancer. Its lead product candidate, tucatinib, is an investigational oral, selective small molecule HER2 inhibitor. Cascadian Therapeutics is conducting a randomized, double-blind controlled pivotal clinical trial called HER2CLIMB, which is comparing tucatinib vs. placebo, each in combination with capecitabine and trastuzumab, in patients with locally advanced or metastatic HER2-positive breast cancer with and without brain metastases, who have previously been treated with a taxane, trastuzumab, pertuzumab and T-DM1. Additional details on HER2CLIMB can be found at or For more information, please visit

Forward-Looking Statements

In order to provide Cascadian Therapeutics' investors with an understanding of its current results and future prospects, this release contains statements that are forward-looking. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include Cascadian Therapeutics' expectations regarding clinical development activities, HER2CLIMB enrollment, timing of additional data, potential benefits of its product candidates, timing of submission of marketing applications, potential regulatory approvals, and its use and adequacy of cash reserves and future financial results.

Forward-looking statements involve risks and uncertainties related to Cascadian Therapeutics' business and the general economic environment, many of which are beyond its control. These risks, uncertainties and other factors could cause Cascadian Therapeutics' actual results to differ materially from those projected in forward-looking statements, including the risks associated with the costs and expenses of developing its product candidates, the adequacy of financing and cash, cash equivalents and investments, changes in general accounting policies, general economic factors, achievement of the results it anticipates from its preclinical development and clinical trials of its product candidates, the receipt of regulatory approvals, and its ability to adequately obtain and protect its intellectual property rights. Although Cascadian Therapeutics believes that the forward-looking statements contained herein are reasonable as of the date hereof, it can give no assurance that its expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of Cascadian Therapeutics' risks and uncertainties, you should review the documents filed by Cascadian Therapeutics with the securities regulators in the United States on EDGAR and in Canada on SEDAR. Cascadian Therapeutics does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except to the extent required by law.

Additional Information
Additional information relating to Cascadian Therapeutics can be found on EDGAR at and on SEDAR at

Condensed Consolidated Statements of Operations
(In thousands except share and per share amounts)
Three months ended
June 30,

Six months ended
June 30,

  20172016 2017 2016 
Operating expenses     
Research and development $   11,514 $  6,380 $   20,101 $  12,717 
General and administrative    3,507    4,365    6,482    10,998 
Intangible asset impairment     —    19,738    —    19,738 
  Total operating expenses     15,021     30,483    26,583    43,453 
  Loss from operations    (15,021)   (30,483)     (26,583)   (43,453)
Other income (expense)     
Investment and other income (expense), net    312    42    472    125 
  Total other income (expense), net    312    42    472    125 
Net loss before income taxes $   (14,709)$  (30,441)$   (26,111)$  (43,328)
Income tax (benefit) provision    —    (6,908)   —    (6,908)
Net loss     (14,709)   (23,533)   (26,111)   (36,420)
Deemed dividend related to beneficial conversion feature on convertible preferred stock    —    (1,599)   (982)   (1,599)
Net loss attributable to common stockholders    (14,709)   (25,132)   (27,093)   (38,019)
Net loss per share — basic and diluted $  (0.30)$  (1.57)$   (0.60)$  (2.39 )
Shares used to compute basic and diluted net loss per share    49,244,348    16,051,836     45,405,430    15,939,412 


Consolidated Balance Sheet Data
(In thousands except share amounts)

As of
    June 30, 2017 December 31, 2016  
 Cash, cash equivalents and investments $  125,415   $  62,805     
 Total assets  $  145,512   $     83,265     
 Long term liabilities $   70   $     135     
 Stockholders' equity $  137,908   $  74,357    
 Common shares outstanding     49,303,172    22,562,640    


Investor and Media Contact:
Monique Greer
Cascadian Therapeutics